NASDAQ$SLN
Silence Therapeutics Plc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Silence Therapeutics reported Q1 2026 revenue of $0.4M and a net loss of $28.5M, with diluted loss per share of $0.11.
Revenue was $0.4 million from the AstraZeneca collaboration vs. $0.1 million a year ago. Net loss was $28.5 million; basic and diluted loss per share was $0.11. R&D on RNAi therapeutics remains the primary use of cash.
- Collaboration revenue $0.4M.
- Net loss $(28.5)M; EPS $(0.11).
- RNAi pipeline (zerlasiran, etc.).
- R&D $9.1M in quarter.
Headline financials
Revenue & EPS history
Silence Therapeutics · Revenue · Quarterly
$422K
Forward guidance
Clinical milestones with AstraZeneca partnership are key forward drivers.
Tailwinds
- Collaboration revenue uptick.
- Focused RNAi platform.
Headwinds
- Substantial quarterly burn.
- Clinical trial risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-2.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+4.4%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+11.3%
Q2 2023
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q1 2026 | -5.8% | -7.7% | -16.3% | |
| Q4 2025 | -6.0% | +4.2% | -0.7% | |
| Q3 2025 | +2.9% | +7.7% | +11.5% | |
| Q2 2025 | +0.2% | +5.1% | +7.0% | |
| Q1 2025 | -1.7% | +26.6% | +31.3% | |
| Q4 2024 | -1.0% | -6.1% | -27.9% | |
| Q3 2024 | -16.7% | -54.3% | -57.7% | |
| Q4 2023 | -8.0% | -7.3% | -14.4% | |
| Q3 2023 | +4.6% | +1.0% | +74.5% | |
| Q2 2023 | +11.3% | +14.2% | +62.6% | |
| Q1 2023 | -7.2% | +1.9% | +3.9% | |
| Q4 2022 | -6.9% | -6.6% | -35.8% | |
| Q3 2022 | +10.7% | +17.4% | +32.1% | |
| Q2 2022 | -2.3% | -3.6% | +22.1% | |
| Q1 2022 | -1.8% | -14.6% | -6.1% | |
| Q4 2021 | -0.8% | +6.7% | +0.6% | |
| Q2 2021 | -14.3% | -11.8% | -9.7% | |
| Q1 2021 | +0.2% | +13.2% | +9.6% | |
| Q4 2020 | +0.2% | +0.2% | +13.7% | |
| Q3 2020 | -2.5% | -9.0% | -13.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro